Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $11.00

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.00.

A number of brokerages have issued reports on PSNL. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BTIG Research cut their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Morgan Stanley cut their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, Needham & Company LLC boosted their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th.

Personalis Price Performance

NASDAQ PSNL opened at $12.59 on Friday. The firm’s 50-day moving average is $8.29 and its two-hundred day moving average is $8.26. Personalis has a 12 month low of $3.84 and a 12 month high of $12.87. The stock has a market capitalization of $1.32 billion, a P/E ratio of -12.34 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. As a group, analysts anticipate that Personalis will post -1.06 EPS for the current year.

Insider Transactions at Personalis

In other news, CFO Aaron Tachibana sold 40,000 shares of Personalis stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $12.01, for a total value of $480,400.00. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,387,984.33. This trade represents a 16.75% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 80,091 shares of Personalis stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $11.02, for a total value of $882,602.82. Following the completion of the transaction, the chief executive officer owned 235,986 shares of the company’s stock, valued at $2,600,565.72. The trade was a 25.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,799 shares of company stock worth $2,031,692 over the last quarter. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently made changes to their positions in PSNL. T. Rowe Price Investment Management Inc. boosted its stake in shares of Personalis by 273.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Personalis by 1,332.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after buying an additional 1,347,439 shares during the period. Kennedy Capital Management LLC boosted its stake in shares of Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after buying an additional 1,281,695 shares during the period. Aberdeen Group plc boosted its stake in shares of Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after buying an additional 861,948 shares during the period. Finally, ARK Investment Management LLC boosted its stake in shares of Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.